<SEC-DOCUMENT>0001641172-25-006421.txt : 20250428
<SEC-HEADER>0001641172-25-006421.hdr.sgml : 20250428
<ACCEPTANCE-DATETIME>20250428160508
ACCESSION NUMBER:		0001641172-25-006421
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250428
DATE AS OF CHANGE:		20250428

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001359931
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				204580525
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88372
		FILM NUMBER:		25880222

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		646-844-0337

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVENUE SOUTH
		STREET 2:		3RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ArTara Therapeutics, Inc.
		DATE OF NAME CHANGE:	20200110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROTEON THERAPEUTICS INC
		DATE OF NAME CHANGE:	20060420

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opaleye Management Inc.
		CENTRAL INDEX KEY:			0001595855
		ORGANIZATION NAME:           	
		EIN:				205648796
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		ONE BOSTON PLACE
		STREET 2:		SUITE 2600
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02108
		BUSINESS PHONE:		617-904-9195

	MAIL ADDRESS:	
		STREET 1:		ONE BOSTON PLACE
		STREET 2:		SUITE 2600
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02108
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001493152-24-046391</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Opaleye Management Inc. -->
          <cik>0001595855</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001359931</issuerCik>
        <issuerName>Protara Therapeutics, Inc.</issuerName>
        <issuerCusip>74365U107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>345 PARK AVENUE SOUTH</com:street1>
          <com:street2>3RD FLOOR</com:street2>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10010</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Opaleye Management, Inc.</reportingPersonName>
      <citizenshipOrOrganization>MA</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>1730000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>1730000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1730000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>4.71</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Protara Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>345 Park Avenue South, 3rd Floor, New York, NY, 10010</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Opaleye Management, Inc.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>One Boston Place, 26th Fl., Boston MA 02108</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Massachusetts</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>1,730,000</amountBeneficiallyOwned>
        <classPercent>4.71</classPercent>
        <numberOfSharesPersonHas>
          <sharedPowerOrDirectToVote>1,730,000</sharedPowerOrDirectToVote>
          <sharedPowerOrDirectToDispose>1,730,000</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Opaleye Management, Inc.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ James Silverman</signature>
        <title>President</title>
        <date>04/28/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
